Baseline characteristics
|
Age at entry | 36 (33–45) | 47 (31–69) | |
Disease duration (years) | 9 (2–20) | 4 (1–15) | |
Women/men | 4/3 | 3/5 | |
Prednisone use at entry (No (%)) | 2 (29) | 4 (50) | |
Erosion at entry (No (%)) | 6 (86) | 5 (63) | |
Baseline arthritis activity
|
Tender joint count | 33 (23–43) | 26 (21.5–39) | |
Swollen joint count | 19 (17–33) | 20.5 (11.5–29.5) | |
Response in arthritis
|
ACR20 (No (%)) |
8 Weeks | 1 (14) | 0 | 0.46 |
16 Weeks | 3 (43) | 0 | 0.08 |
PsARC (No (%)) |
8 Weeks | 4 (57) | 2 (25) | 0.31 |
16 Weeks | 4 (57) | 2 (25) | 0.31 |
Baseline psoriasis activity* | (n=7) | (n=7) | |
PASI score | 3.2 (1.4–6.1) | 5.35 (1.5–10.7) | |
Response in psoriasis (No (%))† |
8 Weeks | 1 (14) | 1 (13) | 1.00 |
16 Weeks | 3 (43) | 0 | 0.08 |